Endotoxin removal is one of the most persistent bottlenecks in bringing therapeutic bacteriophages to market. Produced by the outer membrane of Gram-negative bacteria, endotoxins (lipopolysaccharides, or LPS) can trigger severe immune reactions in patients if not reduced to ultra-low levels. For a Contract Development and Manufacturing Organization (CDMO), especially one producing phage therapies at GMP […]